In part 1 of 5, panel moderator gives an overview of the Special Report focusing on the approval of Xanomeline and tropism chloride capsules for schizophrenia.
Back
Embracing New Therapies in Schizophrenia Management
Embracing New Therapies in Schizophrenia Management
Episodes
All
All
In part 2 of 5, experts discuss the unique mechanism of xanomeline and trospium choloride capsules for the treatment of schizozphrenia.
In part 3 of 5, experts discuss the pivotal trials evaulating xanomeline and trospium chloride capsules (Cobenfy) for schizophrenia.
In part 4 of 5, experts discuss medication adherence to schizophrenia treatments, particularly of xanomeline and trospium choloride capsules for schizophrenia.
In part 5 of 5, experts discuss ongoing unmet needs and future research priorities in schizophrenia management.
Advertisement
Advertisement
Trending on HCPLive
1
Alpha-Gal Syndrome: Closing an Underrecognized Allergy Diagnostic Gap
2
Pelacarsen Misses Primary Endpoint in Lp(a)HORIZON Phase 3 Trial
3
GRI-0621 Improves FVC, Reduces Fibrotic Biomarkers in IPF
4
ORFAN-MAESTRIA: AI Predicts Cardioembolic Stroke, Atrial Fibrillation from CT Scans
5